Erasca (ERAS) Expected to Announce Earnings on Tuesday

Key Points

• Q1 2026 earnings: Erasca will report before the market opens on May 12, with analysts forecasting (-$0.19) EPS and an earnings call set for May 15 at 4:00 PM ET.
• Analyst view vs. market price: The stock carries a consensus rating of "Moderate Buy" with an average target of $17.88, while shares recently traded at $9.93 (down 2%) and the 12‑month range is $1.06–$24.28.
• Insider and institutional activity: Two insiders sold large blocks (20,000 and 80,000 shares) earlier this year; insiders own 14.40% of shares while institutional investors hold about 67.78%.

Erasca (NASDAQ:ERAS - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Erasca to post earnings of ($0.19) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Erasca (NASDAQ:ERAS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Erasca Trading Down 2.0%

NASDAQ ERAS traded down $0.21 during trading on Tuesday, reaching $9.93. The company's stock had a trading volume of 1,743,549 shares, compared to its average volume of 7,320,585. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -22.61 and a beta of 0.68. Erasca has a 12 month low of $1.06 and a 12 month high of $24.28. The firm has a 50 day moving average price of $15.84 and a 200 day moving average price of $9.12.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Citigroup reissued a "buy" rating on shares of Erasca in a report on Friday, March 13th. Piper Sandler boosted their price objective on shares of Erasca from $11.00 to $18.00 and gave the company an "overweight" rating in a report on Friday, March 13th. Stifel Nicolaus upped their target price on Erasca from $20.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, April 27th. HC Wainwright upped their target price on Erasca from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Friday, March 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.88.

Insider Buying and Selling

In related news, insider Shannon Morris sold 20,000 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $15.04, for a total transaction of $300,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ebun Garner sold 80,000 shares of the company's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $16.40, for a total value of $1,312,000.00. Following the sale, the insider owned 25,076 shares of the company's stock, valued at approximately $411,246.40. This represents a 76.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 14.40% of the company's stock.

Institutional Trading of Erasca

Institutional investors and hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC bought a new stake in shares of Erasca during the 4th quarter worth $112,000. Cerity Partners LLC lifted its stake in Erasca by 62.8% in the 2nd quarter. Cerity Partners LLC now owns 57,817 shares of the company's stock valued at $73,000 after purchasing an additional 22,313 shares during the last quarter. Captrust Financial Advisors lifted its stake in Erasca by 13.6% in the 2nd quarter. Captrust Financial Advisors now owns 54,111 shares of the company's stock valued at $69,000 after purchasing an additional 6,486 shares during the last quarter. Abel Hall LLC bought a new position in Erasca in the 4th quarter valued at approximately $58,000. Finally, New York State Common Retirement Fund lifted its stake in Erasca by 39.1% in the 2nd quarter. New York State Common Retirement Fund now owns 37,360 shares of the company's stock valued at $47,000 after purchasing an additional 10,501 shares during the last quarter. 67.78% of the stock is currently owned by institutional investors.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.